Show simple item record

dc.contributor.authorDing, Huiping
dc.contributor.authorCzoty, Paul W.
dc.contributor.authorKiguchi, Norikazu
dc.contributor.authorCami-Kobeci, Gerta
dc.contributor.authorSukhtankar, Devki D.
dc.contributor.authorNader, Michael A.
dc.contributor.authorHusbands, Stephen M.
dc.contributor.authorKo, Mei-Chuan
dc.identifier.citationDing H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, Husbands SM, Ko MC (2016) 'A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates', Proceedings of the National Academy of Sciences, 113 (37), pp.E5511-E5518.en_US
dc.description.abstractDespite the critical need, no previous research has substantiated safe opioid analgesics without abuse liability in primates. Recent advances in medicinal chemistry have led to the development of ligands with mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP) receptor agonist activity to achieve this objective. BU08028 is a novel orvinol analog that displays a similar binding profile to buprenorphine with improved affinity and efficacy at NOP receptors. The aim of this preclinical study was to establish the functional profile of BU08028 in monkeys using clinically used MOP receptor agonists for side-by-side comparisons in various wellhoned behavioral and physiological assays. Systemic BU08028 (0.001-0.01 mg/kg) produced potent long-lasting (i.e., >24 h) antinociceptive and antiallodynic effects, which were blocked by MOP or NOP receptor antagonists. More importantly, the reinforcing strength of BU08028 was significantly lower than that of cocaine, remifentanil, or buprenorphine in monkeys responding under a progressive-ratio schedule of drug self-administration. Unlike MOP receptor agonists, BU08028 at antinociceptive doses and ?10-to 30-fold higher doses did not cause respiratory depression or cardiovascular adverse events as measured by telemetry devices. After repeated administration, the monkeys developed acute physical dependence on morphine, as manifested by precipitated withdrawal signs, such as increased respiratory rate, heart rate, and blood pressure. In contrast, monkeys did not show physical dependence on BU08028. These in vivo findings in primates not only document the efficacy and tolerability profile of bifunctional MOP/NOP receptor agonists, but also provide a means of translating such ligands into therapies as safe and potentially abusefree opioid analgesics.en_US
dc.publisherNational Academy of Sciencesen_US
dc.rightsYellow - can archive pre-print (ie pre-refereeing)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.subjectrespiratory depressionen_US
dc.subjectN/ofq peptide receptoren_US
dc.subjectMu opioid peptide receptoren_US
dc.subjectphysical dependenceen_US
dc.subjectreinforcing effectsen_US
dc.subjectSubject Categories::B200 Pharmacology, Toxicology and Pharmacyen_US
dc.titleA novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primatesen_US
dc.contributor.departmentWake Forest Universityen_US
dc.contributor.departmentUniversity of Bathen_US
dc.identifier.journalProceedings of the National Academy of Sciencesen_US
dc.description.notefull text from

Files in this item


This item appears in the following Collection(s)

Show simple item record

Yellow - can archive pre-print (ie pre-refereeing)
Except where otherwise noted, this item's license is described as Yellow - can archive pre-print (ie pre-refereeing)